Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OLMA 
Olema Pharmaceuticals Inc (OLMA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: OLMA (3-star) is a STRONG-BUY. BUY since 11 days. Simulated Profits (42.25%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $36.5
1 Year Target Price $36.5
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 195.78% | Avg. Invested days 35 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.22B USD | Price to earnings Ratio - | 1Y Target Price 36.5 |
Price to earnings Ratio - | 1Y Target Price 36.5 | ||
Volume (30-day avg) 8 | Beta 2.08 | 52 Weeks Range 2.86 - 29.51 | Updated Date 12/5/2025 |
52 Weeks Range 2.86 - 29.51 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.76 |
Earnings Date
Report Date 2025-11-10 | When - | Estimate -0.4702 | Actual -0.49 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.41% | Return on Equity (TTM) -59.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1859875901 | Price to Sales(TTM) - |
Enterprise Value 1859875901 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.33 | Shares Outstanding 80159923 | Shares Floating 49613660 |
Shares Outstanding 80159923 | Shares Floating 49613660 | ||
Percent Insiders 2.57 | Percent Institutions 89.16 |
Upturn AI SWOT
Olema Pharmaceuticals Inc
Company Overview
History and Background
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for womenu2019s cancers. Founded in 2019, it is headquartered in San Francisco, California. The company's focus is on developing therapies that address resistance mechanisms to existing treatments.
Core Business Areas
- Oncology Drug Development: Focuses on developing targeted therapies for breast and other women's cancers, particularly those resistant to endocrine therapies.
Leadership and Structure
Sean P. Bohen, M.D., Ph.D. serves as President and Chief Executive Officer. The company operates with a structure typical of a clinical-stage biotech, focused on R&D and clinical trials.
Top Products and Market Share
Key Offerings
- OP-1250: Olema's lead product candidate, OP-1250, is a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) being developed for the treatment of estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Market share data is not yet applicable as the drug is in clinical trials. Competitors include other SERDs and endocrine therapies developed by companies like AstraZeneca, Radius Health, and Menarini.
Market Dynamics
Industry Overview
The oncology market, particularly for breast cancer therapies, is large and growing, driven by an aging population and increased incidence rates. There is significant unmet need for therapies that overcome resistance to existing treatments.
Positioning
Olema is positioned as a company developing next-generation endocrine therapies for breast cancer, specifically targeting resistance mechanisms. Their competitive advantage lies in OP-1250's potential to be more effective in patients who have progressed on existing therapies.
Total Addressable Market (TAM)
The global breast cancer therapeutics market is projected to reach hundreds of billions of dollars. Olema is positioned to capture a portion of this market with OP-1250, targeting patients who have developed resistance to existing endocrine therapies.
Upturn SWOT Analysis
Strengths
- Novel CERAN/SERD mechanism of action (OP-1250)
- Focus on unmet need in ER+ HER2- breast cancer
- Experienced management team
- Strong financial position
Weaknesses
- Reliance on a single lead product candidate
- Clinical trial risks and regulatory hurdles
- Limited commercial infrastructure
- Relatively young company
Opportunities
- Potential to expand OP-1250 to other indications
- Strategic partnerships with larger pharmaceutical companies
- Positive clinical trial results could drive significant value
- Acquisition by a larger pharmaceutical company
Threats
- Competition from other companies developing endocrine therapies
- Clinical trial failures
- Regulatory setbacks
- Patent challenges
Competitors and Market Share
Key Competitors
- AZN
- SNY
- LLY
- PFE
Competitive Landscape
Olema faces competition from established pharmaceutical companies with existing endocrine therapies. Its competitive advantage lies in the potential for OP-1250 to overcome resistance to these therapies.
Growth Trajectory and Initiatives
Historical Growth: Olema's historical growth is reflected in the advancement of OP-1250 through clinical trials and the expansion of its research pipeline.
Future Projections: Future growth is heavily dependent on the success of OP-1250's clinical trials. Analyst estimates vary widely depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include the ongoing clinical trials for OP-1250 and the exploration of combination therapies.
Summary
Olema Pharmaceuticals is a clinical-stage biotech with a promising lead candidate, OP-1250, targeting breast cancer. Success in clinical trials is crucial for its growth. The company's financial health is strong, but it faces significant competition. Investors should closely monitor clinical trial updates and regulatory milestones.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Olema Pharmaceuticals Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data for OLMA and its comparables is estimated and may not reflect exact figures. Investments in pharmaceutical companies are inherently risky. Please conduct thorough research and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Olema Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2020-11-19 | President, CEO & Director Dr. Sean P. Bohen M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 122 | Website https://olema.com |
Full time employees 122 | Website https://olema.com | ||
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.